Corporate Overview
Founded in 2006, Cempra Pharmaceuticals is a privately held, clinical-stage pharmaceutical company focused on developing antibacterials to meet critical medical needs. Two lead antibacterial products, both in clinical trials, address the urgent and increasing need for new treatments targeting drug-resistant bacterial infections in both the hospital and the community. Cempra is committed to developing commercially and medically differentiated products that provide a treatment alternative to address patient needs and provide a fair financial return on investment. The company is also utilizing its series of proprietary lead compounds from our novel macrolide library for uses such as the treatment of chronic inflammatory diseases, endocrine diseases and gastric motility disorders.
Addressing the need for novel antibiotics that act against drug-resistant bacteria.
Antibiotic resistance has been a rising threat to human health for several years. Effectiveness of many antibacterial agents has declined worldwide limiting physicians' options to treat serious infections. Adding to the threat is a decline in development of new and novel antibiotics that target resistant pathogens by the pharmaceutical industry. Antibiotic drug resistance has a significant impact on mortality and contributes heavily to healthcare system costs worldwide. The World Health Organization has stated that antibiotic resistance is one of the greatest healthcare challenges for the future. Cempra is focused on developing solutions to this problem and addressing the future needs of patients.
Cempra's two clinical-stage compounds, CEM-101 and TAKSTA™ (CEM-102, sodium fusidate), target the growing problem of antimicrobial resistance. Both are in development as solid and liquid oral formulations. CEM-101 is also being developed in an IV formulation.
CEM-101, a novel fluoroketolide, is active against macrolide-resistant bacteria and is more active than azithromycin or clarithromycin against most macrolide-susceptible bacteria. CEM-101 will enter Phase II clinical development in early 2010.
TAKSTA (sodium fusidate) is an agent with a long history of safety and efficacy outside the U.S. It is active against gram-positive pathogens, including both hospital- and community-acquired methicillin-resistant S. aureus (MRSA). Cempra's loading dose regimen innovation is designed to maximize efficacy and bacterial coverage while minimizing resistance development. TAKSTA will enter Phase III clinical studies in acute bacterial skin and skin structure infections, including wounds and cellulitis, in early 2010.
Led by an accomplished management team dedicated to shape the future of the company and the industry.
Cempra is led by a management team with extensive drug development and commercialization experience in the area of anti-infectives. The company is supported by a world-class Scientific Advisory Board comprised of renowned industry and infectious disease experts and a committed syndicate of experienced investors.
Founded in 2006, Cempra Pharmaceuticals is a privately held, clinical-stage pharmaceutical company focused on developing antibacterials to meet critical medical needs. Two lead antibacterial products, both in clinical trials, address the urgent and increasing need for new treatments targeting drug-resistant bacterial infections in both the hospital and the community. Cempra is committed to developing commercially and medically differentiated products that provide a treatment alternative to address patient needs and provide a fair financial return on investment. The company is also utilizing its series of proprietary lead compounds from our novel macrolide library for uses such as the treatment of chronic inflammatory diseases, endocrine diseases and gastric motility disorders.Addressing the need for novel antibiotics that act against drug-resistant bacteria.
Antibiotic resistance has been a rising threat to human health for several years. Effectiveness of many antibacterial agents has declined worldwide limiting physicians' options to treat serious infections. Adding to the threat is a decline in development of new and novel antibiotics that target resistant pathogens by the pharmaceutical industry. Antibiotic drug resistance has a significant impact on mortality and contributes heavily to healthcare system costs worldwide. The World Health Organization has stated that antibiotic resistance is one of the greatest healthcare challenges for the future. Cempra is focused on developing solutions to this problem and addressing the future needs of patients.
Cempra's two clinical-stage compounds, CEM-101 and TAKSTA™ (CEM-102, sodium fusidate), target the growing problem of antimicrobial resistance. Both are in development as solid and liquid oral formulations. CEM-101 is also being developed in an IV formulation.
CEM-101, a novel fluoroketolide, is active against macrolide-resistant bacteria and is more active than azithromycin or clarithromycin against most macrolide-susceptible bacteria. CEM-101 will enter Phase II clinical development in early 2010.
TAKSTA (sodium fusidate) is an agent with a long history of safety and efficacy outside the U.S. It is active against gram-positive pathogens, including both hospital- and community-acquired methicillin-resistant S. aureus (MRSA). Cempra's loading dose regimen innovation is designed to maximize efficacy and bacterial coverage while minimizing resistance development. TAKSTA will enter Phase III clinical studies in acute bacterial skin and skin structure infections, including wounds and cellulitis, in early 2010.
Led by an accomplished management team dedicated to shape the future of the company and the industry.
Cempra is led by a management team with extensive drug development and commercialization experience in the area of anti-infectives. The company is supported by a world-class Scientific Advisory Board comprised of renowned industry and infectious disease experts and a committed syndicate of experienced investors.